Natixis Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Natixis Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$358K	Buy	14,441 +1,410	+11%	+$33.6K	﹤0.01%	1616
2025 Q4	$304K	Sell	13,031 -44,716	-77%	-$996K	﹤0.01%	1546
2025 Q3	$1.14M	Sell	57,747 -14,396	-20%	-$296K	﹤0.01%	1273
2025 Q2	$1.57M	Buy	72,143 +9,153	+15%	+$216K	﹤0.01%	1164
2025 Q1	$1.53M	Buy	62,990 +3,737	+6%	+$84.2K	﹤0.01%	1161
2024 Q4	$1.24M	Buy	59,253 +13,616	+30%	+$293K	﹤0.01%	1243
2024 Q3	$907K	Buy	45,637 +12,491	+38%	+$232K	﹤0.01%	1323
2024 Q2	$513K	Buy	+33,146	New	+$516K	﹤0.01%	1429
2024 Q1	–	Sell	-12,097	Closed	-$203K	–	1536
2023 Q4	$203K	Buy	+12,097	New	+$165K	﹤0.01%	1516
2023 Q1	–	Sell	-15,367	Closed	-$286K	–	1470
2022 Q4	$286K	Buy	+15,367	New	+$237K	﹤0.01%	1403

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Natixis Advisors's CPRX Position: Q1 2026 in Review

Natixis Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 11% in Q1 2026, buying an estimated $33.6K and bringing the position to 14,441 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #1616.

Natixis Advisors first reported a position in CPRX in Q4 2022 and has held it in 10 quarters since. The position peaked at $1.57M in Q2 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Natixis Advisors held 14,441 shares of Catalyst Pharmaceutical worth $358K as of Q1 2026.
Natixis Advisors bought 1,410 Catalyst Pharmaceutical shares in Q1 2026, an estimated $33.6K.
Catalyst Pharmaceutical made up ﹤0.01% of Natixis Advisors's portfolio in Q1 2026, its #1616 holding.
Natixis Advisors first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 10 quarters since.
Natixis Advisors's Catalyst Pharmaceutical position peaked at $1.57M in Q2 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Natixis Advisors's 13F filing for Q1 2026, filed 13 May 2026.